| Family: | JPMorgan Chase |
| Name: | JPMorgan Healthcare Leaders ETF |
| Inception Date: | 1-Nov-2023 |
| Termination Date: | |
| Investment Objective: | The Fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies (Healthcare Companies) which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. The Fund will invest in common stocks of Healthcare Companies across all market capitalizations, but expects to invest a majority of its assets in mid- and large- capitalization companies. The Fund will invest globally, including in both developed and emerging market countries, although it expects to invest a majority of its Assets in Healthcare Companies located in the U.S. |
| Prospectus | |
| Top 10 Holdings | ||
| ABBVIE INC COMMON STOCK | ABBV | 6.9978% |
| ELI LILLY AND COMPANY | LLY | 6.8242% |
| UNITEDHEALTH GROUP INC | UNH | 6.1342% |
| JOHNSON & COMMON | JNJ | 4.8218% |
| ASTRAZENECA PLC COMMON | AZN | 4.5727% |
| MERCK & CO INC COMMON | MRK | 4.2161% |
| BRISTOL-MYERS SQUIBB CO | BMY | 3.6091% |
| THERMO FISHER SCIENTIFIC | TMO | 3.1911% |
| INTUITIVE SURGICAL INC | ISRG | 2.9623% |
| CVS HEALTH CORP COMMON | CVS | 2.7131% |
| Top 10 Holdings Weight: | 46.0% |
| Number of Holdings: | 68 |
| Shares Outstanding: | 200,000 |
| Total Net Assets: | 11,108,520 |
| NAV: | 55.63 |
| Net Expense Ratio: | 0.65% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Funds Combining Developed & Emerging Exposure |
| Country: | |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Global |
